(e1239) Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
For Wegovy, cite the SELECT trial (20% reduction in major cardiovascular events)
Indeed, it is this synergistic, two-pronged approach combining pharmacotherapy with behaviour change that is likely to achieve more meaningful results than either intervention in silo
This is the piece patients describe as lifechanging
J Int Soc Sports Nutr
While Ozempic might not be a direct treatment for diverticulitis, a healthcare provider might still consider its benefits for weight management and associated conditions like type 2 diabetes